Booking Holdings (BKNG) Q1 2025 Earnings Call April 29, 2025 04:30 PM ET Company Participants Glenn Fogel - CEO, President & DirectorEwout Steenbergen - Executive VP & CFOMark Mahaney - Senior Managing DirectorBrian Nowak - Managing Director Kevin Kopelman - Managing Director - Equity Research Conference Call Participants Douglas Anmuth - Managing Director & Internet AnalystEric Sheridan - AnalystLee Horowitz - AnalystKen Gawrelski - Analyst Operator Welcome to Booking Holdings First Quarter twenty twenty f ...

Edison International (EIX) Q1 2025 Earnings Call April 29, 2025 04:30 PM ET Company Participants Sam Ramraj - Vice President of Investor RelationsPedro Pizarro - President, CEOMaria Rigatti - Executive VP & CFONicholas Campanella - DirectorMichael Lonegan - Director - Equity ResearchSteven Powell - President, CEO, Southern California EdisonCarly Davenport - Vice President, Equity ResearchConstantine Lednev - Vice President - Equity ResearchPaul Zimbardo - Managing DirectorRichard Sunderland - Equity Researc ...

Financial Data and Key Metrics Changes - For Q1 2025, NOV reported revenues of $2.1 billion, a 2% decrease year over year, with net income of $73 million or $0.19 per fully diluted share [4][14] - Adjusted EBITDA was $252 million, representing a 5% increase, with EBITDA margins expanding by 80 basis points to 12% [5][14] - The company generated $135 million in cash from operations and $51 million in free cash flow, with a cash balance increase of $689 million over the last twelve months [15][16] Business Line Data and Key Metrics Changes - The Energy Products and Services segment generated revenue of $992 million, a 2% decrease year over year, with EBITDA declining to $145 million or 14.6% of sales [16][18] - The Energy Equipment segment reported revenue of $1.15 billion, down 3% from the previous year, but EBITDA increased by $46 million to $165 million, resulting in a margin of 14.4% [21][24] - Capital equipment sales accounted for 57% of the Energy Equipment segment's revenues, with bookings for Q1 at $437 million, a 12% year-over-year increase [22][24] Market Data and Key Metrics Changes - International revenues decreased from 65% to 61% of total revenues, attributed to seasonal factors, but the international market is expected to grow as a share of the business [60] - North American activity is anticipated to decline in the double-digit range, while international markets, particularly in unconventional resources, are expected to perform better [60][68] Company Strategy and Development Direction - The company is focusing on operational efficiencies and careful cost management in light of emerging macroeconomic headwinds [6][9] - NOV is well-positioned for long-term growth, emphasizing the importance of deepwater and international shale production as future sources of incremental oil supply [11][41] - The company is actively diversifying supply chains to mitigate tariff impacts and is leveraging its U.S. manufacturing footprint to enhance competitiveness [30][39] Management's Comments on Operating Environment and Future Outlook - Management expressed caution regarding the geopolitical and macroeconomic environment, anticipating challenges in the second half of 2025 [29][41] - The outlook for offshore production remains robust, with expectations for more awards for FPSOs in 2025 compared to previous years [24][50] - Management highlighted the importance of technological advancements in improving drilling and production efficiencies, particularly in deepwater projects [45][46] Other Important Information - The company plans to pay a supplemental dividend of around $80 million, subject to Board approval, to align returns to 50% of excess free cash flow for 2024 [15] - NOV's backlog of capital equipment and projects has grown steadily, with margins improving significantly over the past four years [8][9] Q&A Session Summary Question: Guidance on 2025 margins relative to 2024 - Management indicated that EBITDA margins are expected to be flattish from the first half to the second half of 2025, with modest growth anticipated [56] Question: International revenues decrease - Management acknowledged a seasonal pullback but expects international revenues to grow as a share of the business going forward [60] Question: Capital equipment order activity - Management noted strong confidence in the offshore deepwater market, with potential FPSO awards in 2025, despite some macroeconomic uncertainties [66][68] Question: Tariff mitigation efforts and CapEx - Most mitigation plans do not require significant CapEx, focusing instead on operational efficiency and vendor collaboration [80] Question: M&A opportunities in the current economic environment - Management remains open to opportunistic M&A but emphasized the need for deals to make industrial sense and provide high returns [86][89]

Financial Data and Key Metrics Changes - Total revenues for Q2 2020 were $278 million, driven by record product sales, with a year-to-date total of $513 million [21][5] - Product sales from oncology franchises totaled $240 million, reflecting a 51% increase from the previous year [22] - R&D expenses increased to $198 million in Q2 and $393 million for the first half of 2020, indicating a focus on pipeline investment [24] Business Line Data and Key Metrics Changes - ADCETRIS net sales were $168 million in Q2, with a full-year guidance maintained at $675 million to $700 million [6][25] - PADCEV net sales in the U.S. were $57 million in Q2, a 66% increase from Q1, with full-year guidance set at $215 million to $235 million [7][25] - TUKYSA generated $16 million in revenue in its first partial quarter post-launch [10] Market Data and Key Metrics Changes - The company reported strong adoption of PADCEV for metastatic urothelial cancer, with ongoing trials to expand its use [8][9] - TUKYSA is being positioned in the market for HER2 positive breast cancer, with approvals in multiple countries [10][11] Company Strategy and Development Direction - The company aims to expand the indications for its commercial brands and is advancing over a dozen early-stage assets in clinical and preclinical development [14] - A virtual R&D day is planned to provide more details on the pipeline and commitment to first-in-class therapies [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory despite challenges posed by the COVID-19 pandemic [5] - Positive feedback from KOLs on clinical data supports the potential for accelerated approvals in various indications [13][90] Other Important Information - The company ended Q2 with $896 million in cash and investments, bolstered by the sale of Immunomedics shares [24] - The company is refining its guidance for R&D expenses to a range of $820 million to $870 million for 2020 [25] Q&A Session Summary Question: Insights on TUKYSA's initial launch - Management noted it is early in the launch but is pleased with the awareness and uptake in both academic and community settings [41][42] Question: Factors affecting PADCEV's guidance - Management indicated that while the initial uptake has been strong, growth rates may slow as the launch progresses, with guidance reflecting a 35% to 55% growth rate in the second half [44][47] Question: Gating factors for BLA filing for TV - Management is actively working towards a BLA submission and is encouraged by the positive data from the pivotal trial [51][54] Question: Initial launch feedback for TUKYSA - There is significant enthusiasm among doctors regarding TUKYSA, and it is being used in both patients with and without brain metastases [58][61] Question: Details on the INNO2VATE trial - The trial is focused on evaluating the role of tisotumab vedotin as a single agent or in combination with other therapies for cervical cancer [67] Question: PADCEV usage in frontline settings - Management confirmed ongoing trials to evaluate PADCEV in combination with KEYTRUDA in frontline metastatic disease [75][78]

Entergy (ETR) Q1 2025 Earnings Call April 29, 2025 04:16 PM ET Speaker0 Good morning. My name is Greg, and I will be your conference operator today. At this time, I would like to welcome everyone to the Entergy Corporation First Quarter Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. Thank you. I will now turn the call over to Liz Hunter, Vice President of Investor Relations for Entergy Co ...

Paccar (PCAR) Q1 2025 Earnings Call April 29, 2025 04:16 PM ET Speaker0 Good morning, and welcome to PACCAR's First Quarter twenty twenty five Earnings Conference Call. All lines will be in listen only mode until the question and answer session. Today's call is being recorded. And if anyone has an objection, you should disconnect at this time. I would now like to introduce Mr. Ken Hastings, PACCAR's Director, Investor Relations. Mr. Hastings, please go ahead. Speaker1 Good morning. We would like to welcome ...

Seagen (SGEN) Q3 2020 Earnings Call April 29, 2025 04:13 PM ET Speaker0 Good day, and welcome to the C Gen Third Quarter twenty twenty Financial Results Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Ms. Peggy Pinkston, Vice President of Investor Relations. Please go ahead. Speaker1 Thank you, operator, and good afternoon, everyone. I'd like to welcome all of you to C Gen's third quarter twenty twenty f ...

Seagen (SGEN) Q1 2020 Earnings Call April 29, 2025 04:11 PM ET Speaker0 Good day, and welcome to the Seattle Genetics First Quarter twenty twenty Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference over to Ms. Peggy Pinkston, Vice President of Investor Relations. Please go ahead. Speaker1 Thank you, operator, and good afternoon, everyone. I'd like to welcome all of you to Seattle Genetics first quarter twenty twenty conference call. With me to ...

Seagen (SGEN) FY 2020 Annual General Meeting April 29, 2025 04:09 PM ET Speaker0 Good day and welcome to the Seattle Genetics twenty twenty Annual Meeting of Shareholders. Today's meeting is being recorded. Towards the ending of the meeting we'll have a question and answer session. You can submit questions or comments at any time by clicking on the message icon. It is now my pleasure to turn today's meeting over to Clay Segal, Chairman, President and Chief Executive Officer. Doctor. Segal, please go ahead. ...

Community Bank System (CBU) Q1 2025 Earnings Call April 29, 2025 04:00 PM ET Speaker0 Good day, and welcome to the Community Financial System Inc. First Quarter twenty twenty five Earnings Conference Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference over to Dimitar Karaivanov, President and CEO. Please go ahead. Speaker1 Thank you, Segar. Good ...